We are live on ! Find out more
CYAD

Celyad Oncology SA American Depositary Shares
CYAD

Delisted

CYAD was delisted on the 18th of May, 2023.

Back to rankings

7 hedge funds and large institutions have $8.75M invested in Celyad Oncology SA American Depositary Shares in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less capital invested

Capital invested by funds: $9.23M → $8.75M (-$477K)

22% less funds holding

Funds holding: 9 → 7 (-2)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
7
Holders Change
-2
Holders Change %
-22.22%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$506K
2
Wells Fargo
Wells Fargo
California
+$40.8K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$110K
2
Millennium Management
Millennium Management
New York
-$35.4K
3
UBS Group
UBS Group
Switzerland
-$9.25K
4
Morgan Stanley
Morgan Stanley
New York
-$2.69K
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
1
Victory Capital Management
Texas
$8.33M +$506K +50,227 +6%
Morgan Stanley
2
Morgan Stanley
New York
$314K -$2.69K -267 -0.8%
Wells Fargo
3
Wells Fargo
California
$99K +$40.8K +4,047 +68%
UBS Group
4
UBS Group
Switzerland
$7K -$9.25K -918 -56%
Bank of Montreal
5
Bank of Montreal
Ontario, Canada
$1K – – –
Millennium Management
6
Millennium Management
New York
$126 -$35.4K -3,518 -22%
Renaissance Technologies
7
Renaissance Technologies
New York
– -$110K -10,300 Closed

CYAD Hedge Fund Activity: Q3 2020 in Review

7 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q3 2020, worth a combined $8.75M — down 5.2% from $9.23M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of CYAD and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Victory Capital Management, adding an estimated $506K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $110K sold.

  • 7 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q3 2020, down from 9 in Q2 2020.
  • Funds reported $8.75M of Celyad Oncology SA American Depositary Shares stock for Q3 2020, down 5.2% quarter-over-quarter.
  • 0 funds opened new Celyad Oncology SA American Depositary Shares positions in Q3 2020 and 2 closed out, a net change of -2 holders.
  • The largest Celyad Oncology SA American Depositary Shares buyer in Q3 2020 was Victory Capital Management, an estimated $506K added.
  • The largest Celyad Oncology SA American Depositary Shares seller in Q3 2020 was Renaissance Technologies, an estimated $110K sold.

Based on aggregated 13F filings for Q3 2020.